Introduction {#section1-2058738419868101}
============

Health of the oral cavity is the result of a balance between bacteria and the immune response. When this balance is broken, pathogenic bacteria (PB) increase, and beneficial bacterial species are suppressed, so periodontal disease may develop.^[@bibr1-2058738419868101][@bibr2-2058738419868101][@bibr3-2058738419868101][@bibr4-2058738419868101][@bibr5-2058738419868101][@bibr6-2058738419868101]--[@bibr7-2058738419868101]^

Periodontal treatment consists of mechanical debridement aimed to reduce bacterial loading in the oral cavity.^[@bibr8-2058738419868101]^ Periodontal therapy aims to restore a more favourable oral biofilm.^[@bibr8-2058738419868101]^ Mechanical debridement reduces the total bacterial loading, but the recolonisation of the oral cavity from PB starts shortly after therapy.^[@bibr8-2058738419868101]^ Non-surgical periodontal therapy is widely accepted as a method to keep the natural teeth and preserve oral health, and home oral hygiene is also very important.^[@bibr8-2058738419868101]^ The objective of home oral hygiene consists in the elimination of infection and prevention of disease progression. It is now well established that prevention consists in the control of PB, in supportive periodontal therapy, and that the maintenance of oral health is related to proper prevention care programmes. Although preventive protocols are demonstrated to be widely effective, periodontal disease may present relapse caused by poor oral hygiene. The use of topical antimicrobials has proven to be effective for the treatment of periodontal disease in addition to non-surgical periodontal therapy. In particular, nanomaterial has much potential in dentistry due to difficulties with antibiotic resistance.^[@bibr9-2058738419868101][@bibr10-2058738419868101][@bibr11-2058738419868101]--[@bibr12-2058738419868101]^ These nanoparticles show synergistic antibacterial and antibiofilm effects in clinical and standard strains.^[@bibr11-2058738419868101]^ Different local drug-delivery systems with chemical devices have been introduced; used at the base of the pocket, they minimise the adverse impact on non-oral body sites.^[@bibr13-2058738419868101][@bibr14-2058738419868101][@bibr15-2058738419868101][@bibr16-2058738419868101][@bibr17-2058738419868101]--[@bibr18-2058738419868101]^

Aim {#section2-2058738419868101}
===

The aim of this study was to evaluate the efficacy of a new oral gel formulation named ADC (didecyldimethylammonium chloride) in reducing periodontal bacteria using polymerase chain reaction (PCR).

Materials and methods {#section3-2058738419868101}
=====================

Gel preparation {#section4-2058738419868101}
---------------

The ADC gel is a new formulation based on the complex silver-2-mercaptobenzoate, chlorhexidine digluconate and didecyldimethylammonium chloride as active ingredients. The silver complex, prepared according to the procedure described in the patent application IT 102018000000576, was mixed with the two organic surfactants in distilled water and the solution was then gelified with hydroxypropyl cellulose and polyvinylpyrrolidone. The gel contains didecyldimethylammonium at 0.5%, chlorhexidine digluconate at 0.1% and Ag+ ions at 0.001%. ADC gel is selected for this study for its antibacterial properties as described in the patent application IT 102018000000576.

### In vitro microbiological test {#section5-2058738419868101}

A total of 10 specimens were used. The antimicrobial activity of ADC gel was evaluated in vitro against gram-positive and gram-negative bacteria and *Candida albicans*. ADC gel (50 μL) was added in the centre of a Petri dish containing TSA (Tryptone Soya Agar), previously contaminated at the surface with 100 μL of a microbial pool containing *Staphylococcus aureus* ATCC 6538, *Escherichia coli* ATCC 10536, *Pseudomonas aeruginosa* ATCC 15442, *Enterococcus hirae* ATCC 10541 and *Candida albicans* ATCC 1023 in concentration of the order of 1.5 − 5 × 10^10^ cfu/mL (Diagnostic International Distribution S.p.A, Milan, Italy). The minimum inhibitory concentration of a microbial pool (including periodontal pathogen bacteria) in concentration of 10,000,000 cfu/mL was 0.3% w/w. The results of the in vitro test show the remarkable inhibition of the microbial growth observed after 24 h of incubation at 36°C.

### Cell viability test {#section6-2058738419868101}

PrestoBlue^™^ Reagent Protocol (Invitrogen, Carlsbad, CA, USA) was used to evaluate the viability of cells treated with Ag solutions at different concentrations. Cells used for viability test were human gingival fibroblasts.

Cell lines were seeded into 96-well plates at a density of 104 cells per well containing 100 µL of cell culture medium. In all, 1:2 serial dilutions of the stock solution (initial concentration 0.07%) were made with the culture medium.

After 24 h of incubation, cell viability was measured using PrestoBlue reagent protocol (Invitrogen). The percentage of viable cells was determined by comparing the average absorbance in drug-treated wells with the average absorbance in control wells exposed to vehicle alone. The results were presented as the mean ± standard deviation of three measures.

Experimental design and patient selection {#section7-2058738419868101}
-----------------------------------------

A total of 20 patients with a diagnosis of chronic periodontitis (PD), \>25 years, were selected. The exclusion criteria included medically compromised patients, subjects who had been administered antibiotics or antimicrobials in the past 6 months and pregnant and lactating mothers. None of these patients had received any surgical or non-surgical periodontal therapy and demonstrated radiographic evidence of moderate bone loss. The 20 patients were allotted into two groups of 10 patients each, homogeneous by age and sex. The test group received a bottle containing ADC gel, while the control group received an identical one containing placebo, similar to ADC in consistence, colour, taste and odour. All patients were required to perform a proper home oral hygiene for 15 days. During the initial phase, all the subjects were trained about proper home care techniques and monitored during the study period, receiving full mouth scaling and root planning. Sub-gingival samples of four sites, one in each quadrant, of greatest probing depth in each patient were used. The microbiological analyses were performed at baseline and at day 15. The research objectives were explained to the patients, who then signed an informed consent form. This study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of 06.09.2013 prot. n. 29579 University Study of L'Aquila.

### Microbiological test {#section8-2058738419868101}

LABtest^®^ (LAB SRL^®^, Ferrara, Italy) was used.^[@bibr19-2058738419868101]^ It detects *Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Tannerella forsythia, Treponema denticola, Fusobacterium nucleatum, Campylobacter rectus* and total bacteria loading.

### Real-time PCR {#section9-2058738419868101}

Primers and probe oligonucleotides were designed based on 16S rRNA gene sequences of the Human Oral Microbiome Database (HOMD 16S rRNA RefSeq Version 10.1) counting 845 entries. All the sequences were aligned to find either consensus sequence or less conserved spots. Three real-time PCR runs were performed for each sample. The first reaction quantifies the total amount of bacteria using two degenerate primers and a single probe matching a highly conserved sequence of the 16S ribosomal RNA gene. The second reaction detects and quantifies the three red complex bacteria, that is, *Porphyromonas gingivalis, Tannerella forsythia* and *Treponema denticola*, in a multiplex PCR. The third reaction detects and quantifies *Aggregatibacter actinomycetemcomitans, Fusobacterium nucleatum* and *Campylobacter rectus*. These reactions include six primers each and three probes each that were highly specific for each species. Oligonucleotide concentrations and PCR conditions were optimised to ensure sensitivity, specificity and no inhibition in the case of unbalanced target amounts. Absolute quantification assays were performed using the Applied Biosystems 7500 Sequence Detection System (Thermo Fisher Scientific, Monza, Italy). The amplification profiles were initiated by a 10-min incubation period at 95°C to activate polymerase, followed by a two-step amplification of 15 s at 95°C and 60 s at 57°C for 40 cycles. All experiments were performed including non-template controls to exclude reagent contamination.

### Agents (S1) 125 {#section10-2058738419868101}

Plasmids containing synthetic DNA target sequences (Eurofins MWG Operon, Ebersberg, Germany) were standardly used for the quantitative analysis. Standard curves for each target were constructed in a triplex reaction using a mix of the same amount of plasmids in serial dilutions ranging from 10 to 107 copies. There was a linear relationship between the threshold cycle values plotted against the log of the copy number over the entire range of dilutions (data not shown). The copy numbers for individual plasmid preparations were estimated using the Thermo NanoDrop spectrophotometer (Thermo Fisher Scientific).

The absolute quantification of total bacterial genome copies in samples allowed for the calculation of the relative amount of specific bacterial species. To prevent sample and PCR contamination, plasmid purification and handling were performed in a separate laboratory with dedicated pipettes.

Statistical analysis {#section11-2058738419868101}
--------------------

Descriptive statistics were performed using Microsoft Excel 2016 spreadsheets. Paired t test from SPSS program was used to statistically evaluate the change in specific bacteria loading before and after treatment.

Results {#section12-2058738419868101}
=======

The retrieved samples of sub-gingival plaque were investigated to detect the microbial positivity to six different bacterial species and to evaluate the total bacterial loading by quantitative PCR ([Table 1](#table1-2058738419868101){ref-type="table"}). The evaluation showed a statistically significant reduction in total bacterial loading in pre- and post-treatment phases (*P* = 0.029; [Table 2](#table2-2058738419868101){ref-type="table"}) in the experimental group. In the control group, the reduction in total bacterial loading was not significant (*P* = 0.279; [Tables 3](#table3-2058738419868101){ref-type="table"} and [4](#table4-2058738419868101){ref-type="table"}).

###### 

Mean microbial count of specific bacterial species before and after ADC treatment.

![](10.1177_2058738419868101-table1)

           Bacteria              Mean ± SD
  -------- --------------------- -----------------------
  Pair 1   AA1                   104.1 ± 329.2
  AA2      871.6 ± 2348.3        
  Pair 2   CR1                   123.5 ± 172.5
  CR2      227.8 ± 683.3         
  Pair 3   FN1                   2601.9 ± 2895.5
  FN2      5621.0 ± 10,188.2     
  Pair 4   TBL1                  505,001.8 ± 514,769.3
  TBL2     67,015.6 ± 84,934.2   
  Pair 5   TD1                   83.1 ± 160.4
  TD2      73.1 ± 207.2          
  Pair 6   TF1                   111.2 ± 208.8
  TF2      107.8 ± 311.2         

SD: standard deviation; AA: *Aggregatibacter actinomycetemcomitans*; CR: *Campylobacter rectus*; FN: *Fusobacterium nucleatum*; TBL: total bacteria loading; TD: *Treponema denticola*; TF: *Tannerella forsythia*; 1: before and 2: after treatment.

###### 

Comparison between total bacterial loading in pre- and post-treatment phases in ADC treated sites.

![](10.1177_2058738419868101-table2)

                       Mean ± SD               95% confidence interval of the difference   Sig.        
  -------- ----------- ----------------------- ------------------------------------------- ----------- -------
  Pair 1   AA1-AA2     −767.5 ± 2413.4         −2494.0                                     958.9       0.341
  Pair 2   CR1-CR2     −104.3 ± 744.8          637.1                                       428.5       0.668
  Pair 3   FN1-FN2     −3019.1 ± 11,290.2      −11,095.6                                   5057.4      0.420
  Pair 5   TBL1-TBL2   437,986.2 ± 534,870.8   55,362.6                                    820,609.8   0.029
  Pair 6   TD1-TD2     11.8 ± 284.4            −191.7                                      215.3       0.899
  Pair 7   TF1-TF2     3.4 ± 402.2             −284.3                                      291.1       0.979

SD: standard deviation; AA: *Aggregatibacter actinomycetemcomitans*; CR: *Campylobacter rectus*; FN: *Fusobacterium nucleatum*; TBL: total bacteria loading; TD: *Treponema denticola*; TF: *Tannerella forsythia*.

###### 

Mean microbial count of specific bacterial species of control group treated with placebo.

![](10.1177_2058738419868101-table3)

  Comparison between specific bacteria before and after treatment   Bacterial species before and after treatment   Mean ± SD
  ----------------------------------------------------------------- ---------------------------------------------- ---------------------
  Pair 1                                                            AA1                                            94.2 ± 29.8
  AA2                                                               416.5 ± 131.7                                  
  Pair 2                                                            CR1                                            5812.0 ± 1837.9
  CR2                                                               8271.7 ± 2615.7                                
  Pair 3                                                            FN1                                            91,389.2 ± 28,899.8
  FN2                                                               61,032.8 ± 19,300.3                            
  Pair 4                                                            PG1                                            49,860.5 ± 15,767.3
  PG2                                                               28,850.4 ± 9123.3                              
  Pair 5                                                            TBL1                                           1,217,938 ± 385,145
  TBL2                                                              211,880 ± 67,002                               
  Pair 6                                                            TD1                                            11,372.9 ± 3596.4
  TD2                                                               15,010.1 ± 4747.6                              
  Pair 7                                                            TF1                                            6592.1 ± 2084.6
  TF2                                                               5443.3 ± 1721.3                                

SD: standard deviation; AA: *Aggregatibacter actinomycetemcomitans*; CR: *Campylobacter rectus*; FN: *Fusobacterium nucleatum*; PG: *Porphyromonas gingivalis*; TBL: total bacteria loading; TD: *Treponema denticola*; TF: *Tannerella forsythia*; 1: before and 2: after treatment.

###### 

Comparison between total bacterial loading in pre- and post-placebo phases.

![](10.1177_2058738419868101-table4)

  Comparison between specific bacteria before and after treatment   Bacterial species before and after treatment   Mean value and standard deviation   95% confidence interval of the difference               
  ----------------------------------------------------------------- ---------------------------------------------- ----------------------------------- ------------------------------------------- ----------- -------
  Pair 1                                                            AA1-AA2                                        −101 ± 322                          −332                                        128         0.343
  Pair 2                                                            CR1-CR2                                        191 ± 7361                          −5074                                       5457        0.936
  Pair 3                                                            FN1-FN2                                        3620 ± 113,755                      −77,755                                     84,996      0.922
  Pair 4                                                            PG1-PG2                                        5211 ± 55,789                       −34,697                                     45,121      0.774
  Pair 5                                                            TBL1-TBL2                                      386,915 ± 1,062,470                 −373,130                                    1,146,961   0.279
  Pair 6                                                            TD1-TD2                                        406 ± 9209                          −6181                                       6994        0.892
  Pair 7                                                            TF1-TF2                                        1454 ± 4322                         −1637                                       4546        0.315

SD: standard deviation; AA: *Aggregatibacter actinomycetemcomitans*; CR: *Campylobacter rectus*; FN: *Fusobacterium nucleatum*; PG: *Porphyromonas gingivalis*; TBL: total bacteria loading; TD: *Treponema denticola*; TF: *Tannerella forsythia*.

Discussion {#section13-2058738419868101}
==========

In the oral cavity, bacterial infection induces an inflammatory response with progressive destruction of the periodontal tissues and finally the loss of teeth. The definition of PD has changed considerably over the years.^[@bibr20-2058738419868101]^ Specific PB of the biofilm formed by plaque causes PD. The PB leak into the periodontal ligament space causing anaerobic infection creates a cascade of events, which ends with the production of inflammatory mediators and bacterial metabolites. PD affects about 50% of adults or more, while the severe form of PD affects around 10% (range: 5%--20%) of adults and the moderate PD around 30%. In the elderly, aged 60--74, the prevalence of PD is estimated at about 70%--90%.^[@bibr21-2058738419868101]^

PB associated with periodontal diseases is susceptible to a variety of antiseptics and antibiotics. Non-surgical periodontal therapy, associated with proper domestic oral hygiene, has been documented to preserve the natural dentition by achieving and maintaining a healthy periodontium.^[@bibr22-2058738419868101]^ According to the current state of knowledge, species such as red complex organisms are just a few of those PB that have been shown to play a major role in the pathogenesis of PD.^[@bibr6-2058738419868101]^

In this study, a strong reduction in total bacterial loading using ADC for domestic oral hygiene was observed. The reduction in total bacteria can be attributed to the domestic use of the gel and its antibacterial properties.

Since there was no control group, it is difficult to draw final conclusions about the clinical efficiency of ADC, although the reported data show a drop in the total bacterial loading after treatment. It is our knowledge that a randomised controlled trial is mandatory to have final proof about the efficacy of the new molecule to reduce bacterial loading inside the periodontal pocket.

The oral cavity is the interface between the human body and the external world. The external layer of the oral epithelium is composed of various epithelia, which constitute barriers guaranteeing the integrity of the organism and protecting it from invasion by PB. It is well known that PD is pathology-associated with PB. Genetic differences in oral plaque, background and general health of patients can control the development of PD.^[@bibr6-2058738419868101]^

The association of PD and systemic diseases, such as diabetes, cardiovascular diseases and pre-term birth, reveals the underestimated importance of this disease for global health. A thorough and early diagnosis of PD allows a more accurate risk calculation for developing systemic pathologies.^[@bibr23-2058738419868101]^ If a causative relationship is established between PD and these pathologies, therapeutic management of PD will become a part of their prevention.^[@bibr24-2058738419868101],[@bibr25-2058738419868101]^

Conclusion {#section14-2058738419868101}
==========

A wide range of PB has been discovered in various niches in the oral cavity. Their potential roles in regulating the oral environment in both health and disease have also been successfully described in the literature. They have been conserved in evolution and show a relatively higher potential to PD onset, and thus potentially deregulate the biofilm environment and progressing gingival and periodontal diseases. Not just this but also the role of PB in controlling the spread of caries has also been documented. Challenges such as their design, synthesis and function at the molecular level need to be overcome in the near future to open doors towards the design of potentially effective oral microbial antibiotics.

The results of the study provide preliminary data on an overall reduction in bacterial loading with use of ADC (*P* = 0.029). Since there was no control group, it is difficult to draw final conclusions about the clinical efficiency of ADC, although the reported data show a statistically significant drop in total bacterial loading after treatment.

We believe a randomised controlled clinical trial is mandatory to have final proof about the efficacy of the new molecule to reduce specific and total bacterial loading inside the periodontal pocket.
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